80125-14-0

Basic information

• Product Name: Remoxipride
• Synonyms: (S)-Remoxipride;3-Bromo-2,6-dimethoxy-N-[[(2S)-1-ethyl-2-pyrrolidinyl]methyl]benzamide;3-Bromo-2,6-dimethoxy-N-[[[2S,(-)]-1-ethylpyrrolidine-2α-yl]methyl]benzamide;3-Bromo-N-[[(2S)-1-ethyl-2-pyrrolidinyl]methyl]-2,6-dimethoxybenzamide;(S)-3-BroMo-N-((1-ethylpyrrolidin-2-yl)Methyl)-2,6-diMethoxybenzaMide;REMOXIPRIDE;Remoxipride [USAN:BAN:INN];(S)-3-Bromo-N-[(1-ethyl-2-pyrrolidinyl)methyl]-2，6-dimethoxybenzamide
• CAS NO: 80125-14-0
• Molecular Formula: C₁₆H₂₃BrN₂O₃
• Molecular Weight: 371.27
• Mol File: 80125-14-0.mol
• Article Data: 2

Chemical Properties

• Boiling Point: 439.9°C at 760 mmHg
• Flash Point: 219.8°C
• Appearance: /
• Density: 1.292
• Vapor Pressure: 6.17E-08mmHg at 25°C
• Refractive Index: 1.54
• Storage Temp.: 2-8°C
• PKA: pKa 8.9 (Uncertain)
• CAS DataBase Reference: Remoxipride(CAS DataBase Reference)
• NIST Chemistry Reference: Remoxipride(80125-14-0)
• EPA Substance Registry System: Remoxipride(80125-14-0)

Safety Data

• Hazardous Substances Data: 80125-14-0(Hazardous Substances Data)

Usage

Description

Remoxipride is an atypical antipsychotic drug that acts as a D2 receptor blocker. It is known for its effectiveness in treating schizophrenia with fewer extrapyramidal symptoms (EPS) and autonomic side effects compared to traditional antipsychotics like haloperidol. Remoxipride has been shown to diminish negative symptoms of schizophrenia and is considered a promising candidate for the development of new antipsychotic medications with improved safety profiles.

Uses

Used in Pharmaceutical Industry:
Remoxipride is used as an antipsychotic medication for the treatment of schizophrenia. It is effective in managing both positive and negative symptoms of the disorder, with a lower risk of side effects compared to traditional antipsychotics.
Used in Research and Development:
Remoxipride serves as a valuable compound in the research and development of new antipsychotic drugs. Its unique structure and mechanism of action provide insights into the development of more selective and safer antipsychotic medications, potentially with fewer side effects and improved efficacy.

InChI:InChI=1/C16H23BrN2O3/c1-4-19-9-5-6-11(19)10-18-16(20)14-13(21-2)8-7-12(17)15(14)22-3/h7-8,11H,4-6,9-10H2,1-3H3,(H,18,20)

Upstream product

• 73219-89-3 3-bromo-2,6-dimethoxybenzoic acid 
• 1466-76-8 2-6-dimethoxybenzoic acid 
• 22795-99-9 (S)-2-(Aminomethyl)-1-ethylpyrrolidine 
• 84225-91-2 5-bromo-2,6-dimethoxybenzoic acid chloride 
• 84277-13-4 di-D-(-)-tartrate salt of (S)-2-aminomethyl-1-ethylpyrrolidine 

Relevant articles and documents

3-Aminomethylbiphenyls. A New Class of Dopamine Receptor Ligands

A series of 3-aminomethylbiphenyls were prepared in three steps from 3-phenylbenzoic acid and their affinities for the D2, D3 and D4 dopamine receptor subtypes determined. Most of the compounds described contained unique amine subunits of known dopaminergic agents. The compounds containing the amino tails present in the antipsychotic drugs haloperidol, pimozide and miliperidine displayed selectivity for the D2 receptor. Five-fold selectivity for the D4 receptor was observed in the compound 1-(3-biphenyl)-4-(2-pyrimidyl)piperazine. This selectivity for D4 vs. D2 receptors is comparable to that observed with the atypical antipsychotic clozapine.